Article

FDA Approves Preloaded Syringe for Wet AMD

Author(s):

Lucentis treats wet age-related macular degeneration and macular edema after retinal vein occlusion.

The FDA recently approved a pre-filled syringe to administer ranibizumab (Lucentis PFS/Genentech-Roche).

The device will be available early next year.

Like the Lucentis 0.5mg vial, the syringe is approved to treat people with wet age-related macular degeneration (AMD), and macular edema after retinal vein occlusion (RVO). Having a prefilled syringe should make it easier and safer for physicians to administer the eye injection, the company said in a news release.

An estimated 1.1 million people in the United States have wet AMD. The drug was approved to treat the condition in 2006.

It is a vascular endothelial growth factor inhibitor designed to bind to and inhibit the protein that plays a role in angiogenesis and hyperpermeability of blood vessels.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Psychiatric pharmacist and patient -- Image credit: NanSan | stock.adobe.com
Psychiatric pharmacist -- Image credit: HBS | stock.adobe.com
2 experts are featured in this series.